Tabernero, Josep

Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer

Prager, G. W., Taieb, J., Fakih, M., Ciardiello, F., Van Cutsem, E., Elez, E., Cruz, F. M., Wyrwicz, L., Stroyakovskiy, D., Pápai, Z., et al. (2023) · New England Journal of Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 467

Fruquintinib versus Placebo in Patients with Refractory Metastatic Colorectal Cancer (FRESCO-2): An International, Multicentre, Randomised, Double-Blind, Phase 3 Study

Dasari, A., Lonardi, S., Garcia-Carbonero, R., Elez, E., Yoshino, T., Sobrero, A., Yao, J., García-Alfonso, P., Kocsis, J., Cubillo Gracian, A., et al. (2023) · The Lancet

Colorectal Cancer Treatments and StudiesAngiogenesis and VEGF in Cancer

Cited by 368

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

Hodi, F. S., Ballinger, M., Lyons, B., Soria, J.-C., Nishino, M., Tabernero, J., Powles, T., Smith, D., Hoos, A., McKenna, C., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersMedical Imaging Techniques and Applications

Cited by 366

Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer

Tabernero, J., Van Cutsem, E., Díaz-Rubio, E., Cervantes, A., Humblet, Y., André, T., Van Laethem, J.-L., Soulié, P., Casado, E., Verslype, C., et al. (2007) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 337

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

Bedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 324

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Melisi, D., Garcia-Carbonero, R., Macarulla, T., Pezet, D., Deplanque, G., Fuchs, M., Trojan, J., Oettle, H., Kozloff, M., Cleverly, A., et al. (2018) · British Journal of Cancer

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 294

LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

Pascual-García, M., Bonfill-Teixidor, E., Planas-Rigol, E., Rubio-Perez, C., Iurlaro, R., Arias, A., Cuartas, I., Sala-Hojman, A., Escudero, L., Martínez-Ricarte, F., et al. (2019) · Nature Communications

Cancer Immunotherapy and BiomarkersImmune cells in cancer

Cited by 262

Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies

Sveen, A., Bruun, J., Eide, P. W., Eilertsen, I. A., Ramirez, L., Murumägi, A., Arjama, M., Danielsen, S. A., Kryeziu, K., Elez, E., et al. (2018) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 256

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer

van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 232

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Van Cutsem, E., Huijberts, S., Grothey, A., Yaeger, R., Cuyle, P.-J., Elez, E., Fakih, M., Montagut, C., Peeters, M., Yoshino, T., et al. (2019) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 224

Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors

Herpers, B., Eppink, B., James, M. I., Cortina, C., Cañellas-Socias, A., Boj, S. F., Hernando-Momblona, X., Glodzik, D., Roovers, R. C., van de Wetering, M., et al. (2022) · Nature Cancer

Monoclonal and Polyclonal Antibodies ResearchCancer Cells and Metastasis

Cited by 178

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer

Elez, E., Yoshino, T., Shen, L., Lonardi, S., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., et al. (2025) · New England Journal of Medicine

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 166

A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy

Sánchez-Danés, A., Larsimont, J.-C., Liagre, M., Muñoz-Couselo, E., Lapouge, G., Brisebarre, A., Dubois, C., Suppa, M., Sukumaran, V., del Marmol, V., et al. (2018) · Nature

Hedgehog Signaling Pathway StudiesWnt/β-catenin signaling in development and cancer

Cited by 139

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial

Montagut, C., Argilés, G., Ciardiello, F., Poulsen, T. T., Dienstmann, R., Kragh, M., Kopetz, S., Lindsted, T., Ding, C., Vidal, J., et al. (2018) · JAMA Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 135

A combined oncogenic pathway signature of BRAF , KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction

Tian, S., Simon, I., Moreno, V., Roepman, P., Tabernero, J., Snel, M., van't Veer, L., Salazar, R., Bernards, R., & Capella, G. (2013) · Gut

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 128

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF -Mutant Colorectal Cancer

Oddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 121

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

Van Cutsem, E., Eng, C., Nowara, E., Świeboda-Sadlej, A., Tebbutt, N. C., Mitchell, E., Davidenko, I., Stephenson, J., Elez, E., Prenen, H., et al. (2014) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 110

Pharmacogenomic and Pharmacoproteomic Studies of Cetuximab in Metastatic Colorectal Cancer: Biomarker Analysis of a Phase I Dose-Escalation Study

Tabernero, J., Cervantes, A., Rivera, F., Martinelli, E., Rojo, F., von Heydebreck, A., Macarulla, T., Rodriguez-Braun, E., Eugenia Vega-Villegas, M., Senger, S., et al. (2010) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 110

Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy

Linares, J., Sallent-Aragay, A., Badia-Ramentol, J., Recort-Bascuas, A., Méndez, A., Manero-Rupérez, N., Re, D. L., Rivas, E. I., Guiu, M., Zwick, M., et al. (2023) · Nature Communications

Colorectal Cancer Treatments and StudiesCancer Cells and Metastasis

Cited by 109

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

Blons, H., Emile, J. F., Le Malicot, K., Julié, C., Zaanan, A., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J. L., Thaler, J., et al. (2014) · Annals of Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 108

A CT-based Radiomics Signature is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

Ligero, M., Garcia-Ruiz, A., Viaplana, C., Villacampa, G., Raciti, M. V., Landa, J., Matos, I., Martin-Liberal, J., Ochoa-de-Olza, M., Hierro, C., et al. (2021) · Radiology

Radiomics and Machine Learning in Medical ImagingCancer Immunotherapy and Biomarkers

Cited by 107

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

Wainberg, Z. A., Alsina, M., Soares, H. P., Braña, I., Britten, C. D., Del Conte, G., Ezeh, P., Houk, B., Kern, K. A., Leong, S., et al. (2017) · Targeted Oncology

PI3K/AKT/mTOR signaling in cancerColorectal Cancer Treatments and Studies

Cited by 98

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,KRAS Wild-Type, Metastatic Colorectal Cancer

Sclafani, F., Kim, T. Y., Cunningham, D., Kim, T. W., Tabernero, J., Schmoll, H. J., Roh, J. K., Kim, S. Y., Park, Y. S., Guren, T. K., et al. (2015) · Journal of the National Cancer Institute

Colorectal Cancer Treatments and StudiesGrowth Hormone and Insulin-like Growth Factors

Cited by 92

Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer

Dienstmann, R., Salazar, R., & Tabernero, J. (2015) · American Society of Clinical Oncology Educational Book

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 82